Troutman Pepper Advises Palvella Therapeutics in Reverse Merger With Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
December 18, 2024
December 18, 2024
ATLANTA, Georgia, Dec. 18 -- Troutman Pepper, a law firm, issued the following news:
PHILADELPHIA - Troutman Pepper client Palvella Therapeutics, Inc. (NASDAQ: PVLA), a clinical-stage rare disease biopharmaceutical company, recently announced the completion of its previously announced reverse merger with Pieris Pharmaceuticals, Inc. (Pieris). The combined company will operate under the name Palvella Therapeutics, Inc., and its shares began trading on the Nasdaq Capital Market on Dec . . .
PHILADELPHIA - Troutman Pepper client Palvella Therapeutics, Inc. (NASDAQ: PVLA), a clinical-stage rare disease biopharmaceutical company, recently announced the completion of its previously announced reverse merger with Pieris Pharmaceuticals, Inc. (Pieris). The combined company will operate under the name Palvella Therapeutics, Inc., and its shares began trading on the Nasdaq Capital Market on Dec . . .